This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Kyowa Hakko Bio Co., Ltd., Mitsubishi Gas Chemical Company, Inc.. Active years: 2012.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 104 
1 out of 2,304 
Years Active: 2012
Title: Mika Sumi: Innovator in Diabetes Therapeutics
Introduction
Mika Sumi is a notable inventor based in Ibaraki, Japan, recognized for his contributions to the field of diabetes treatment. With a focus on improving insulin resistance, his work aims to provide effective solutions for individuals suffering from type II diabetes. Sumi's innovative approaches have garnered attention in the medical community, making him a key figure in the research and development of therapeutic agents.
Latest Patents
Mika Sumi holds a patent for an insulin resistance improving agent. The objective of this invention is to offer a safe and highly effective therapeutic solution for type II diabetes. The patent features a compound represented by a specific general formula, which encompasses various chemical structures, including lower alkyl and phenyl groups. This innovative agent presents a promising direction for enhancing insulin sensitivity and thereby improving the quality of life for diabetic patients.
Career Highlights
Throughout his career, Mika Sumi has made significant strides in pharmaceutical research. He has worked with renowned companies, including Kyowa Hakko Bio Co., Ltd. and Mitsubishi Gas Chemical Company, Inc. His experience in these organizations has provided him with a solid foundation to pursue innovations in diabetes treatment.
Collaborations
Mika Sumi has collaborated with talented professionals in the industry, including his coworkers Fumiko Ogino and Toshikazu Kamiya. These collaborations have enriched Sumi's research efforts and advanced the development of his patented innovations.
Conclusion
Mika Sumi's dedication to inventing an effective insulin resistance improving agent marks him as a significant innovator in the pharmaceutical field. His commitment to improving therapeutic strategies for type II diabetes highlights the potential for future advancements in managing this pervasive health issue. With continued research and collaboration, Sumi's contributions hold promise for improving patient outcomes in diabetes care.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile